Neurosarcoidosis treated with mycophenolate mofetil: Two cases;Neurosarcoïdose et mycophénolate mofétil

Revue Neurologique

Volumn 163, Issue 4, 2007, Pages 471-475

  Chaussenot, A ^a   Bourg, V ^a   Chanalet, S ^a   Fornari, J M ^b   Lebrun, C ^a  

^a PASTEUR HOSPITAL   (France)

^b Centre de Rééducation Les Cadrans Solaires   (France)

Author keywords

Cyclophosphamide; Infliximab; Mycophenolate mofetil; Neurosarcoidosis; Sarcoidosis

Indexed keywords

ADEFOVIR DIPIVOXIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; ARTICLE; BRAIN DISEASE; CASE REPORT; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMATOLOGY; HUMAN; RADIOLOGY; SARCOIDOSIS; TREATMENT DURATION; TREATMENT OUTCOME; DRUG COMBINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MYCOPHENOLIC ACID; PERIPHERAL NERVOUS SYSTEM DISEASES; SARCOIDOSIS;

EID: 34249990164     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(07)90423-3     Document Type: Article

References (31)

1. ALTSCHULER EL. (2003). The first case of sarcoidosis treated with mycophenolate mofetil. Br J Dermatol, 149: 442.
2. AGBOGU B, STERN B, SEWELL C, YANG G. (1995). Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol, 52: 875-879.
3. BAUGHMAN R, JUDSON M, TEIRSTEIN A et al. (2002). Thalidomide for chronic sarcoidosis. Chest, 122: 227-232.
4. BJERMER L, THUNELL M, ROSENHALL L, STJERNBERG N. (1991). Endobronchial biopsy positive sarcoidosis: relation to bronchoalveolar lavage and course of disease. Respir Med, 85: 229-324.
5. CHAPELON C, ZIZA JM, PIETTE JC et al. (1990). Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine, 69: 261-276.
6. DELANEY P. (1977). Neurological manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med, 87: 336-345.
7. DOTY J, MAZUR J, JUDSON M. (2003). Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest, 124: 2023-2026.
8. DOTY J, MAZUR J, JUDSON M. (2005). Treatment of sarcoidosis with infliximab. Chest, 127: 1064-1071.
9. DUBAS F, NICOLAS G. (2001). Neurosarcoïdose. Encycl Med Chir. (Paris-France), neurology, 17-168-a-10, 8p.
10. FERRIBY D, DE SEZE J, STOJKOVIC T et al. (2000). Manifestations cliniques et approche thérapeutique de la neurosarcoïdose. Rev Neurol (Paris), 156 : 965-975.
11. HUNNINGHAKE GW, COSTABEL U et al. (1999). Statement on sarcoïdosis. Am J respire Crit Care Med, 160: 736-755.
12. KANG S, SUH JH. (1999). Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiat Oncol Invest, 7: 309-312.
13. KATZ JM, BRUNO MK, WINTERKORN JMS et al. (2003). The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch neurol, 60: 426-430.
14. KILMARTIN DJ, FORRESTER JV, DICK AD. (1998). Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet, 352: 35-36.
15. KOUBA DJ, MIMOUNI D, RENCIC A, NOUSARI HC. (2003). Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol, 148: 147-148.
16. LOWER EE, BRODERICK JP, BROTT TG et al. (1997). Diagnosis and management of neurologic sarcoidosis. Arch Intern Med, 157: 1864-1868.
17. MANZ HJ. (1983). Pathobiology of neurosarcoidosis and clinicopathologic correlation. Can J Neurol Sci, 10: 50-55.
18. MATSUO M, EHARA S, TAMAKAWA Y et al. (1995). Muscular sarcoïdosis. Skeletal Radiol, 24: 535-537.
19. MOUGDIL A, PRZYGODZKI RM, KHER KK. (2006). Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol, 21: 281-285.
20. NEWMAN LS, ROSE CS, MAIER LA. (1997). Sarcoidosis. N Engl J Med, 336: 1224-1234.
21. O'CONNOR AS, NAVAB F, GERMAIN MJ, FREMAN JK (2003). Pancreatitis and duodenitis from sarcoidosis: successful therapy with mycophenolate mofetil. Dig Dis Sci, 48: 2191-2195.
22. OKSANEN V. (1986). Neurosarcoidosis: clinical presentation and course in 50 patients. Acta neurol Scand, 73: 283-290.
23. PETTERSEN JA, ZOCHODONE DW, BELL, RB et al. (2002). Refractory neurosarcoidosis responding to infliximab. Neurology, 59: 1660-1661.
24. RAMANAN AV, THIMMARAYAPPA AD, BAILDAM EM. (2002). Muscle involvement in childhood sarcoïdosis and need for muscle biopsy. Ann Rheum Dis, 61: 376-377.
25. SHARMA CP. (1998). Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurologic involvement. Arch Neurol, 55: 1248-1254.
26. STERN BJ, KRUMHOLZ A, JOHNS C et al. (1985). Sarcoidosis and its neurological manifestations. Arch Neurol, 42: 909-917.
27. SILVERSTEIN A, SILTZBACH LE. (1969). Muscle involvement in sarcoïdosis: asymptomatic, myositis, and myopathy. Arch Neurol, 21: 235-241.
28. VERMERSCH P, STOJKOVIC T, DE SEZE J. (2005). mycophenolate mofetil and neurological diseases. Lupus, 14: 1-4.
29. WALLACE SL, LATTES R, MALIA JP, RAGAN C. (1958). Muscle involvement in Boeck's sarcoid. Ann Intern Med, 48: 497-511.
30. ZABEL P, ENTZIAN P, DALHOFF K et al. (1997). Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med, 155: 1665-1669.
31. ZAJICEK JP, SCOLDING NJ, FOSTER O et al. (1999) Central nervous system sarcoidoisis: diagnosis and management. Q J Med, 92: 103-117.